{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:49:56Z","timestamp":1794577796746,"version":"4.9.1"},"reference-count":372,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["73249"],"award-info":[{"award-number":["73249"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178079","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:34:30Z","timestamp":1755693270000},"page":"178079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Targeting STAT3 pathway: A promising immunotherapeutic strategy for triple-negative breast cancer \u2013 Current status and future outlooks"],"prefix":"10.1016","volume":"1005","author":[{"given":"Zahra","family":"Malekinejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz Mehdizadeh","family":"Aghdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza Khodaei","family":"Ardakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emadaldin","family":"Forghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsan","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Simiyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5010-7293","authenticated-orcid":false,"given":"Soheila","family":"Montazersaheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178079_bib1","article-title":"Modulation of hypoxia-induced chemoresistance to polymeric micellar cisplatin: the effect of ligand modification of micellar carrier versus inhibition of the mediators of drug resistance","volume":"10","author":"Abyaneh","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.178079_bib2","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/cancers14112807","article-title":"SCAMP3 regulates EGFR and promotes proliferation and migration of triple-negative breast cancer cells through the modulation of AKT, ERK, and STAT3 signaling pathways","volume":"14","author":"Acevedo-D\u00edaz","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","article-title":"Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A multicenter phase II Trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti\u2013CTLA-4 and anti\u2013PD-1 blockade in rare tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib5","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.3390\/ijms25179276","article-title":"Proteomic investigation of immune checkpoints and some of their inhibitors","volume":"25","author":"Agostini","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib6","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded\u2010access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al\u2010Ali","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2025.178079_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12282-020-01098-9","article-title":"Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and \u03b2-catenin genes","volume":"27","author":"Alkaraki","year":"2020","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mc.23234","article-title":"Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer","volume":"59","author":"Alraouji","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejphar.2025.178079_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00743","article-title":"Carnosol, a natural polyphenol, inhibits migration, metastasis, and tumor growth of breast cancer via a ROS-dependent proteasome degradation of STAT3","volume":"9","author":"Alsamri","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib10","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.3390\/ijms20153696","article-title":"Downregulation of STAT3, \u03b2-catenin, and notch-1 by single and combinations of siRNA treatment enhance chemosensitivity of wild type and doxorubicin resistant MCF7 breast cancer cells to doxorubicin","volume":"20","author":"Alshaer","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2017.00167","article-title":"The IL-6\/STAT3 signaling pathway is an early target of manuka honey-induced suppression of human breast cancer cells","volume":"7","author":"Aryappalli","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","article-title":"Single-cell map of diverse immune phenotypes in the breast tumor microenvironment","volume":"174","author":"Azizi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178079_bib13","doi-asserted-by":"crossref","first-page":"20669","DOI":"10.18632\/oncotarget.7838","article-title":"Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent","volume":"7","author":"Ball","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178079_bib14","doi-asserted-by":"crossref","DOI":"10.31487\/j.COR.2018.10.002","article-title":"STAT3 knockdown induces tumor formation by MDA-MB-231 cells","volume":"1","author":"Banerjee","year":"2018","journal-title":"Clinical oncology and research"},{"key":"10.1016\/j.ejphar.2025.178079_bib15","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/ijc.29923","article-title":"Constitutive activation of STAT3 in breast cancer cells: a review","volume":"138","author":"Banerjee","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib16","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/ijc.29923","article-title":"Constitutive activation of STAT 3 in breast cancer cells: a review","volume":"138","author":"Banerjee","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/13543776.2025.2494857","article-title":"Novel inhibitors of STAT3: an updated patent review (2022\u2013present)","author":"Bao","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejphar.2025.178079_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00280-014-2480-2","article-title":"Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors","volume":"74","author":"Bendell","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib19","series-title":"STAT3 Inhibitors in Cancer: A Comprehensive Update","first-page":"95","author":"Bharadwaj","year":"2016"},{"key":"10.1016\/j.ejphar.2025.178079_bib20","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/s41467-023-38115-2","article-title":"TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression","volume":"14","author":"Bi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178079_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236074","article-title":"Comprehensive live-cell imaging analysis of cryptotanshinone and synergistic drugscreening effects in various human and canine cancer cell lines","volume":"16","author":"Bittner","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178079_bib22","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/ijc.30847","article-title":"Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma","volume":"141","author":"Bixel","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168449","article-title":"Nitric oxide-releasing drug glyceryl trinitrate targets jak2\/stat3 signaling, migration and invasion of triple-negative breast cancer cells","volume":"22","author":"Bouaouiche","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101822","article-title":"STAT3 inhibitor OPB-51602 is cytotoxic to tumor cells through inhibition of complex I and ROS induction","volume":"23","author":"Brambilla","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ejphar.2025.178079_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5152\/eurjrheum.2022.22028","article-title":"Severe infections in patients treated with tocilizumab for systemic diseases other than rheumatoid arthritis: a retrospective multicenter observational study","volume":"10","author":"Broca","year":"2023","journal-title":"European J. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.178079_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110401","article-title":"\"Shedding\" light on HER4 signaling in normal and malignant breast tissues","volume":"97","author":"Brockhoff","year":"2022","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejphar.2025.178079_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cmet.2006.04.014","article-title":"Critical role of STAT3 in leptin's metabolic actions","volume":"4","author":"Buettner","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2025.178079_bib28","first-page":"1752","article-title":"Tocilizumab is associated with increased risk of fungal infections among critically ill patients with COVID-19 and acute renal failure","volume":"13","author":"Burger","year":"2023","journal-title":"An Observat. Cohort Study"},{"key":"10.1016\/j.ejphar.2025.178079_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040436","article-title":"Antitumor activity of pulvomycin via targeting activated-stat3 signaling in docetaxel-resistant triple-negative breast cancer cells","volume":"9","author":"Byun","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178079_bib30","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1021\/acs.jmedchem.2c01115","article-title":"Design, synthesis, and biological activity of marinacarboline analogues as STAT3 pathway inhibitors for docetaxel-resistant triple-negative breast cancer","volume":"66","author":"Byun","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib31","doi-asserted-by":"crossref","first-page":"11351","DOI":"10.1021\/acs.jmedchem.3c00836","article-title":"Platinum(IV) complexes as inhibitors of STAT3 and regulators of the tumor microenvironment to control breast cancer","volume":"66","author":"Cai","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib32","first-page":"3853","article-title":"The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression","volume":"9","author":"Cai","year":"2017","journal-title":"Am. J. Tourism Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.785153","article-title":"Current progress and future perspectives of immune checkpoint in cancer and infectious diseases","volume":"12","author":"Cai","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejphar.2025.178079_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.omtn.2022.06.012","article-title":"DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer","volume":"29","author":"Casas","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178079_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/TCRM.S251668","article-title":"Role of alpelisib in the treatment of PIK3CA-mutated breast cancer: patient selection and clinical perspectives","volume":"17","author":"Chang","year":"2021","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejphar.2025.178079_bib36","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1038\/s41467-018-05852-8","article-title":"Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2\/STAT3 axis","volume":"9","author":"Chang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178079_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17081321","article-title":"Phyto-sesquiterpene lactones prevent the development of multidrug resistance in TNBC via ABC transporters inhibition and STAT3\/MYC signaling","volume":"17","author":"Chang","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminoncol.2020.05.006","article-title":"Early stage triple negative breast cancer: management and future directions","volume":"47","author":"Chaudhary","year":"2020","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2012.12.012","article-title":"MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer","volume":"128","author":"Chen","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib40","first-page":"554","article-title":"Folic acid-modified liposome quercetin induces apoptosis of triple-negative breast cancer cells via mitochondrial apoptosis mediated by JAK2\/STAT3 signaling pathway","volume":"51","author":"Chen","year":"2024","journal-title":"Cancer Res. Prev. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/acscentsci.3c01440","article-title":"Discovery of the highly selective and potent STAT3 inhibitor for pancreatic cancer treatment","volume":"10","author":"Chen","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib42","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1021\/acs.jmedchem.4c02438","article-title":"Auto-RapTAC: a versatile and sustainable platform for the automated rapid synthesis and evaluation of PROTAC","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41419-021-04033-8","article-title":"miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1","volume":"12","author":"Chen","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178079_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109139","article-title":"Tumor-associated macrophages promote migration and invasion via modulating IL-6\/STAT3 signaling in renal cell carcinoma","volume":"111","author":"Chen","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib45","doi-asserted-by":"crossref","DOI":"10.3892\/or.2023.8584","article-title":"Artesunate synergistically promotes sorafenib-induced apoptosis and ferroptosis in non-Hodgkin lymphoma cells through inhibition of the STAT3 pathway","volume":"50","author":"Chen","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib46","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1080\/1061186X.2018.1452244","article-title":"Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer","volume":"26","author":"Chen","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejphar.2025.178079_bib47","first-page":"339","article-title":"Stat3\/Oct-4\/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066","volume":"53","author":"Cheng","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib48","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12929-018-0456-y","article-title":"STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening","volume":"25","author":"Cheng","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib49","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.ejphar.2025.178079_bib50","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","article-title":"XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer","volume":"13","author":"Cheng","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178079_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2045-824X-6-12","article-title":"Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells","volume":"6","author":"Chinchar","year":"2014","journal-title":"Vasc. Cell"},{"key":"10.1016\/j.ejphar.2025.178079_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41540-025-00531-z","article-title":"Personalizing neoadjuvant chemotherapy regimens for triple-negative breast cancer using a biology-based digital twin","volume":"11","author":"Christenson","year":"2025","journal-title":"NPJ Sys. Biol. Applicat."},{"key":"10.1016\/j.ejphar.2025.178079_bib53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13058-023-01684-7","article-title":"Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3\/AKT pathways","volume":"25","author":"Chuangchot","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41523-021-00371-0","article-title":"Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6","volume":"8","author":"Chung","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/ijo.2013.2195","article-title":"STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits","volume":"44","author":"Chung","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx376.001","article-title":"Phase 1b\/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)","volume":"28","author":"Cohen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib57","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1007\/s11033-021-06528-1","article-title":"Atiprimod triggered apoptotic cell death via acting on PERK\/eIF2\u03b1\/ATF4\/CHOP and STAT3\/NF-\u039aB axis in MDA-MB-231 and MDA-MB-468 breast cancer cells","volume":"48","author":"Coker-Gurkan","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib58","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1158\/0008-5472.CAN-20-1379","article-title":"STAT3 and GR cooperate to drive gene expression and growth of basal-like triple-negative breast cancer","volume":"80","author":"Conway","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.lungcan.2006.11.003","article-title":"Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer","volume":"55","author":"Cortas","year":"2007","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.ejphar.2025.178079_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-018-0992-z","article-title":"Osthole inhibits triple negative breast cancer cells by suppressing STAT3","volume":"37","author":"Dai","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-025-07623-8","article-title":"Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages","volume":"211","author":"Dai","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib63","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2025.178079_bib64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13058-024-01925-3","article-title":"NF-\u03baB associated markers of prognosis in early and metastatic triple negative breast cancer","volume":"26","author":"De La Cruz","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib65","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/ijc.28767","article-title":"STAT3 and metabolism: how many ways to use a single molecule?","volume":"135","author":"Demaria","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib66","article-title":"Development and evaluation of polyethylenimine polyplexes as non-viral vectors for delivery of plasmid DNA encoding shRNA against STAT3 activity into triple negative breast cancer cells","volume":"82","author":"Demir-Dora","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejphar.2025.178079_bib67","first-page":"1","article-title":"Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13\/STAT3 circuit","author":"Deng","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2025.178079_bib68","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3892\/or.2015.4160","article-title":"miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression","volume":"34","author":"Deng","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.920514","article-title":"Curcumin and its nano-formulations: defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejphar.2025.178079_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120996","article-title":"Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors","volume":"309","author":"Dinakar","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib72","article-title":"Ginsenoside Rh2 regulates triple-negative breast cancer proliferation and apoptosis via the IL-6\/JAK2\/STAT3 pathway","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib73","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib74","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ddr.22055","article-title":"Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC)","volume":"84","author":"Dogheim","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib75","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejphar.2025.178079_bib77","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.neo.2018.03.004","article-title":"The STAT3 target gene TNFRSF1A modulates the NF-\u03baB pathway in breast cancer cells","volume":"20","author":"Egusquiaguirre","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejphar.2025.178079_bib78","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/jbm.a.34992","article-title":"Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy","volume":"102","author":"Falamarzian","year":"2014","journal-title":"J. Biomed. Mater. Res., Part A"},{"key":"10.1016\/j.ejphar.2025.178079_bib79","doi-asserted-by":"crossref","first-page":"15291","DOI":"10.1021\/acs.jmedchem.4c00872","article-title":"Natural product-inspired discovery of naphthoquinone-furo-piperidine derivatives as novel STAT3 inhibitors for the treatment of triple-negative breast cancer","volume":"67","author":"Fan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib80","doi-asserted-by":"crossref","first-page":"ra16","DOI":"10.1126\/scisignal.2004656","article-title":"Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKC\u03b2II abundance","volume":"7","author":"Farren","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejphar.2025.178079_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031809","article-title":"IL-6 cytokine family: a putative target for breast cancer prevention and treatment","volume":"23","author":"Felcher","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib82","first-page":"4433","article-title":"Safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas","volume":"144","author":"Feldman","year":"2024","journal-title":"Leukemia, Solid Tumors"},{"key":"10.1016\/j.ejphar.2025.178079_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.871667","article-title":"Elaeagnus angustifolia plant extract induces apoptosis via P53 and signal transducer and activator of transcription 3 signaling pathways in triple-negative breast cancer cells","volume":"9","author":"Fouzat","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.ejphar.2025.178079_bib84","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.21873\/anticanres.16994","article-title":"STAT3 contributes a favorable response to pembrolizumab through IFN-\u03b3-induced apoptosis in urothelial cancer","volume":"44","author":"Fuchizawa","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib85","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/acschembio.5b00945","article-title":"Strategies and approaches of targeting STAT3 for cancer treatment","volume":"11","author":"Furtek","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejphar.2025.178079_bib86","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.mce.2013.03.023","article-title":"STAT signaling in different breast cancer sub-types","volume":"382","author":"Furth","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.178079_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106624","article-title":"Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment","volume":"192","author":"Gan","year":"2024","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib88","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","article-title":"HER3 in cancer: from the bench to the bedside","volume":"41","author":"Gandullo-S\u00e1nchez","year":"2022","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"key":"10.1016\/j.ejphar.2025.178079_bib89","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12282-019-00966-3","article-title":"PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation","volume":"26","author":"Gao","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejphar.2025.178079_bib91","doi-asserted-by":"crossref","first-page":"468","DOI":"10.20892\/j.issn.2095-3941.2020.0501","article-title":"SHP-1 acts as a tumor suppressor by interacting with EGFR and predicts the prognosis of human breast cancer","volume":"19","author":"Geng","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib92","first-page":"E4924","volume":"114","author":"Genini","year":"2017"},{"key":"10.1016\/j.ejphar.2025.178079_bib93","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.it.2019.06.004","article-title":"Dendritic cell metabolism and function in tumors","volume":"40","author":"Giovanelli","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejphar.2025.178079_bib94","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.canlet.2012.10.003","article-title":"Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol","volume":"328","author":"Gopalan","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178079_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1571135","article-title":"YX-112, a novel celastrol-derived PROTAC, inhibits the development of triple-negative breast cancer by targeting the degradation of multiple proteins","volume":"16","author":"Gu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116313","article-title":"Targeting the JAK2\/STAT3 signaling pathway with natural plants and phytochemical ingredients: a novel therapeutic method for combatting cardiovascular diseases","volume":"172","author":"Guo","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178079_bib97","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7150\/thno.17237","article-title":"Liposomal nanoparticles carrying anti-IL6R antibody to the tumour microenvironment inhibit metastasis in two molecular subtypes of breast cancer mouse models","volume":"7","author":"Guo","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2025.178079_bib98","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12032-024-02328-2","article-title":"IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3\/HIF-1\u03b1 pathway","volume":"41","author":"Guo","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/md22060252","article-title":"\u03b1O-Conotoxin GeXIVA[1,2] suppresses in vivo tumor growth of triple-negative breast cancer by inhibiting AKT-mTOR, STAT3 and NF-\u03baB signaling mediated proliferation and inducing apoptosis","volume":"22","author":"Guo","year":"2024","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejphar.2025.178079_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03237-y","article-title":"Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer","volume":"43","author":"Guo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib101","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11033-022-08034-4","article-title":"Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2\/STAT5 and PI3K\/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line","volume":"50","author":"Guvenir Celik","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044002","article-title":"Crosstalk of inflammatory cytokines within the breast tumor microenvironment","volume":"24","author":"Habanjar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102137","article-title":"Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3","volume":"35","author":"Hall","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178079_bib104","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1002\/jcb.26767","article-title":"microRNA-30d mediated breast cancer invasion, migration, and EMT by targeting KLF11 and activating STAT3 pathway","volume":"119","author":"Han","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.178079_bib105","article-title":"A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma","volume":"23","author":"Han","year":"2023","journal-title":"BMC Compl. Med.Therapies"},{"key":"10.1016\/j.ejphar.2025.178079_bib106","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib107","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1158\/1535-7163.MCT-18-0508","article-title":"The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models","volume":"17","author":"Handle","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178079_bib108","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/0008-5472.CAN-12-4524-T","article-title":"Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8","volume":"73","author":"Hartman","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib109","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.hoc.2022.08.018","article-title":"Systemic therapy for hereditary breast cancers","volume":"37","author":"Harvey-Jones","year":"2023","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ejphar.2025.178079_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132232","article-title":"The PI3K\/Akt\/mTOR signaling pathway in triple-negative breast cancer: a resistance pathway and a prime target for targeted therapies","volume":"17","author":"Hassan","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib111","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.3390\/cancers13246209","article-title":"The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer","volume":"13","author":"He","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2022.146245","article-title":"STAT3\/HIF1A and EMT specific transcription factors regulated genes: novel predictors of breast cancer metastasis","volume":"818","author":"Hegde","year":"2022","journal-title":"Gene"},{"key":"10.1016\/j.ejphar.2025.178079_bib113","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2020","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ejphar.2025.178079_bib114","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2013-07-517987","article-title":"Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity","volume":"123","author":"Hossain","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178079_bib115","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-024-03501-3","article-title":"Enhanced anti-tumor efficacy of S3I-201 in breast cancer mouse model through Wharton jelly- exosome","volume":"24","author":"Hosseini","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2025.178079_bib116","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib117","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-020-01561-7","article-title":"Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes STAT3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer","volume":"39","author":"Hua","year":"2020","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"key":"10.1016\/j.ejphar.2025.178079_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib119","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejphar.2025.178079_bib120","article-title":"miR-221\/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer","volume":"8","author":"Hwang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178079_bib121","doi-asserted-by":"crossref","first-page":"8974","DOI":"10.3390\/ijms21238974","article-title":"Autophagy and autophagy-related diseases: a review","volume":"21","author":"Ichimiya","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib122","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4049\/jimmunol.1002067","article-title":"Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors","volume":"187","author":"Iwata-Kajihara","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2025.178079_bib123","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s12094-023-03141-5","article-title":"Synergistic effect of chrysin and radiotherapy against triple-negative breast cancer (TNBC) cell lines","volume":"25","author":"Jafari","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib124","first-page":"19","article-title":"Induction of SUSD2 by STAT3 activation is associated with tumor recurrence in HER2-positive","volume":"14","author":"Jeong","year":"2025","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2022.8418","article-title":"MYCL promotes the progression of triple-negative breast cancer by activating the JAK\/STAT3 pathway","volume":"48","author":"Jiang","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib126","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12935-024-03541-9","article-title":"STAT3: key targets of growth-promoting receptor positive breast cancer","volume":"24","author":"Jiang","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2025.178079_bib127","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4149\/neo_2020_190805N716","article-title":"Inhibition of the breast cancer by ppar\u03b3 agonist pioglitazone through jak2\/stat3 pathway","volume":"67","author":"Jiao","year":"2020","journal-title":"Neoplasma"},{"key":"10.1016\/j.ejphar.2025.178079_bib128","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160606","article-title":"Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer","volume":"7","author":"Jin","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2025.178079_bib129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cells9010217","article-title":"Role of JAK\/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial\u2013mesenchymal transition","volume":"9","author":"Jin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178079_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154087","article-title":"A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation","volume":"101","author":"Jin","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejphar.2025.178079_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910458","article-title":"Ginsenoside rh1 prevents migration and invasion through mitochondrial ROS-mediated inhibition of STAT3\/NF-\u03baB signaling in MDA-MB-231 cells","volume":"22","author":"Jin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib132","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/cbin.11456","article-title":"Evaluation of STAT3 decoy oligodeoxynucleotides' synergistic effects on radiation and\/or chemotherapy in metastatic breast cancer cell line","volume":"44","author":"Johari","year":"2020","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejphar.2025.178079_bib133","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib134","series-title":"STAT 3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis","author":"Jones","year":"2016"},{"key":"10.1016\/j.ejphar.2025.178079_bib135","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1002\/ptr.7983","article-title":"Mechanism insights of curcumin and its analogues in cancer: an update","volume":"37","author":"Joshi","year":"2023","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib136","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12195-017-0490-y","article-title":"Phenotypically screened carbon nanoparticles for enhanced combinatorial therapy in triple negative breast cancer","volume":"10","author":"Kampert","year":"2017","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.ejphar.2025.178079_bib137","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02150-4","article-title":"Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR","volume":"23","author":"Kang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib138","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-020-04059-3","article-title":"Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors","volume":"85","author":"Kawazoe","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110991","article-title":"Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma","volume":"39","author":"Kenchappa","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib140","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1038\/s41598-018-27864-6","article-title":"GRAMD1B regulates cell migration in breast cancer cells through JAK\/STAT and Akt signaling","volume":"8","author":"Khanna","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib141","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1016\/j.bmc.2017.06.036","article-title":"Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines","volume":"25","author":"Kim","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib142","article-title":"Primaquine inhibits the endosomal trafficking and nuclear localization of EGFR and induces the apoptosis of breast cancer cells by nuclear EGFR\/Stat3-mediated c-Myc downregulation","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib143","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1038\/s41388-022-02269-y","article-title":"A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response","volume":"41","author":"Kim","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2025.178079_bib144","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/ijms19092708","article-title":"Protein tyrosine phosphatases as potential regulators of STAT3 signaling","volume":"19","author":"Kim","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib145","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1038\/s41418-019-0322-9","article-title":"MEST induces Twist-1-mediated EMT through STAT3 activation in breast cancers","volume":"26","author":"Kim","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2025.178079_bib146","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/cas.13332","article-title":"Interleukin\u20106\/STAT 3 signaling as a promising target to improve the efficacy of cancer immunotherapy","volume":"108","author":"Kitamura","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/biom9050170","article-title":"Novel galiellalactone analogues can target stat3 phosphorylation and cause apoptosis in triple-negative breast cancer","volume":"9","author":"Ko","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.178079_bib148","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.2174\/0929867321666140414100831","article-title":"IL-6 activated JAK\/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma","volume":"21","author":"Kolosenko","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib149","first-page":"8525","article-title":"Prognostic significance of STAT3\/phosphorylated-STAT3 in tumor: a meta-analysis of literatures","volume":"8","author":"Kong","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib150","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib151","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.1158\/0008-5472.CAN-10-1293","article-title":"Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects","volume":"70","author":"Kujawski","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib152","doi-asserted-by":"crossref","first-page":"647","DOI":"10.7150\/thno.16827","article-title":"STAT3\/NF-\u03baB-regulated lentiviral TK\/GCV suicide gene therapy for cisplatin-resistant triple-negative breast cancer","volume":"7","author":"Kuo","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2025.178079_bib153","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.31272","article-title":"Checkpoint inhibitors in triple\u2010negative breast cancer (TNBC): where to go from here","volume":"124","author":"Kwa","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib154","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/ijc.31594","article-title":"Mimetics of suppressor of cytokine signaling 3: novel potential therapeutics in triple breast cancer","volume":"143","author":"La Manna","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib155","first-page":"77","article-title":"Triple-negative breast cancer: new potential therapeutics derived from SOCS3 protein","author":"La Manna","year":"2018","journal-title":"Excit. Role Pept. in Life Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib156","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050720","article-title":"Preclinical and clinical trials of new treatment strategies targeting cancer stem cells in subtypes of breast cancer","volume":"12","author":"Landeros","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178079_bib157","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1038\/ncomms5715","article-title":"Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis","volume":"5","author":"Lee","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178079_bib158","article-title":"Current treatment landscape for early triple-negative breast cancer (TNBC)","volume":"12","author":"Lee","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00491","article-title":"Anti-cancer activity of Centipeda minima extract in triple negative breast cancer via inhibition of AKT, NF-\u03baB, and STAT3 signaling pathways","volume":"10","author":"Lee","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib160","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s43440-025-00721-w","article-title":"Chalcone-9: a novel inhibitor of the JAK-STAT pathway with potent anti-cancer effects in triple-negative breast cancer cells","volume":"77","author":"Lee","year":"2025","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib161","doi-asserted-by":"crossref","first-page":"11121","DOI":"10.1073\/pnas.1300873110","article-title":"Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis","volume":"110","author":"Lee","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2025.178079_bib162","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1073\/pnas.0534764100","article-title":"Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth","volume":"100","author":"Leong","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2025.178079_bib163","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI0215650","article-title":"What does Stat3 do?","volume":"109","author":"Levy","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.178079_bib164","article-title":"Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib165","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01223-x","article-title":"HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib166","first-page":"65","article-title":"Study of kinase inhibitor WP1066 on the STAT3\/JAK2 of prostate stromal cells","volume":"49","author":"Li","year":"2018","journal-title":"J. Sichuan Univ. Med. Sci. Ed."},{"key":"10.1016\/j.ejphar.2025.178079_bib167","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2016.11.003","article-title":"Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-\u03baB\/IL-6 signals","volume":"386","author":"Liang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178079_bib168","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.21873\/anticanres.15871","article-title":"STAT3 inactivation and induction of apoptosis associate with fluoxetine-inhibited epithelial-mesenchymal transition and growth of triple-negative breast cancer in vivo","volume":"42","author":"Liao","year":"2022","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib169","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1039\/b606246f","article-title":"Structure, function, and regulation of STAT proteins","volume":"2","author":"Lim","year":"2006","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ejphar.2025.178079_bib170","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.2147\/OTT.S278013","article-title":"Progress in understanding the IL-6\/STAT3 pathway in colorectal cancer","volume":"13","author":"Lin","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejphar.2025.178079_bib171","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00109-017-1549-x","article-title":"Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells","volume":"95","author":"Liu","year":"2017","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib172","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-018-5052-z","article-title":"GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6\/STAT3 signaling activation","volume":"174","author":"Liu","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib173","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41419-022-04747-3","article-title":"RBMS1 promotes gastric cancer metastasis through autocrine IL-6\/JAK2\/STAT3 signaling","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178079_bib174","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib175","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1021\/acs.jnatprod.8b00247","article-title":"Napabucasin and related heterocycle-fused naphthoquinones as STAT3 inhibitors with antiproliferative activity against cancer cells","volume":"81","author":"L\u00f6cken","year":"2018","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejphar.2025.178079_bib176","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib177","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1381251","article-title":"Potential therapeutic targets of the JAK2\/STAT3 signaling pathway in triple-negative breast cancer","volume":"14","author":"Long","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116500","article-title":"Discovery of novel small molecules targeting the USP21\/JAK2\/STAT3 axis for the treatment of triple-negative breast cancer","volume":"273","author":"Long","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib179","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01071","article-title":"Eupalinolide J Suppresses the growth of triple-negative breast cancer cells via targeting STAT3 signaling pathway","volume":"10","author":"Lou","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117377","article-title":"Discovery of naphthoquinone-furo-piperidone derivatives as dual targeting agents of STAT3 and NQO1 for the treatment of breast cancer","volume":"287","author":"Lou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib181","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1111\/cas.15855","article-title":"Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6\/JAK2\/STAT3 signaling","volume":"114","author":"Lu","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib182","article-title":"Progress and prospect of immunotherapy for triple-negative breast cancer","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib183","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.actbio.2021.07.029","article-title":"Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer","volume":"134","author":"Luo","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejphar.2025.178079_bib184","article-title":"A dual-targeting liposome enhances triple-negative breast cancer chemoimmunotherapy through inducing immunogenic cell death and inhibiting STAT3 activation","volume":"19","author":"Luo","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.ejphar.2025.178079_bib185","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2025.178079_bib186","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.omto.2021.12.025","article-title":"Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells","volume":"24","author":"Lv","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ejphar.2025.178079_bib187","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-020-01197-9","article-title":"LNK promotes the growth and metastasis of triple negative breast cancer via activating JAK\/STAT3 and ERK1\/2 pathway","volume":"20","author":"Lv","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2025.178079_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2024.112661","article-title":"Co-targeting CDK 4\/6 and C-MYC\/STAT3\/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal-transition in triple negative breast cancer by Pt(II) complexes bearing NH3 as trans-co-ligand","volume":"259","author":"Lv","year":"2024","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejphar.2025.178079_bib189","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","article-title":"Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study","volume":"15","author":"Lynce","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178079_bib190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13058-024-01774-0","article-title":"Tbcrc 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer","volume":"26","author":"Lynce","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib191","first-page":"1943","article-title":"Antitumor effects of saikosaponin b2 on breast cancer cell proliferation and migration","volume":"20","author":"Ma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib192","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41388-022-02204-1","article-title":"TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer","volume":"41","author":"Ma","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2025.178079_bib193","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11030-022-10490-w","article-title":"Screening of potent STAT3-SH2 domain inhibitors from JAK\/STAT compound library through molecular dynamics simulation","volume":"27","author":"Manoharan","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejphar.2025.178079_bib194","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.866014","article-title":"IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment","volume":"12","author":"Manore","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib195","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.3390\/cancers13205197","article-title":"HMGA2 supports cancer hallmarks in triple-negative breast cancer","volume":"13","author":"Mansoori","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166228","article-title":"Activation of CD44-Lipoprotein lipase axis in breast cancer stem cells promotes tumorigenesis","volume":"1867","author":"Manupati","year":"2021","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2025.178079_bib197","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3390\/cancers11111756","article-title":"Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer","volume":"11","author":"Marhelava","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib198","series-title":"Seminars in Cancer Biology","first-page":"96","article-title":"Transmembrane (TMEM) protein family members: poorly characterized even if essential for the metastatic process","author":"Marx","year":"2020"},{"key":"10.1016\/j.ejphar.2025.178079_bib199","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12013-019-00873-6","article-title":"Diarylidenylpiperidones, H-4073 and HO-3867, induce G2\/M cell-cycle arrest, apoptosis and inhibit STAT3 phosphorylation in human pancreatic cancer cells","volume":"77","author":"Mast","year":"2019","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2025.178079_bib200","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1158\/0008-5472.CAN-13-3470","article-title":"STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious","volume":"74","author":"Maycotte","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib201","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti\u2013programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib202","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.clbc.2023.12.001","article-title":"Concurrent use of statins in patients undergoing curative intent treatment for triple negative breast cancer: a systematic review and meta-analysis","volume":"24","author":"McKechnie","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib203","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.3390\/cancers12123529","article-title":"Current progresses and challenges of immunotherapy in triple-negative breast cancer","volume":"12","author":"Mediratta","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib204","doi-asserted-by":"crossref","first-page":"18074","DOI":"10.1021\/acsami.9b01343","article-title":"Pro-nifuroxazide self-assembly leads to triggerable nanomedicine for anti-cancer therapy","volume":"11","author":"Misra","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejphar.2025.178079_bib205","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3390\/cancers12051107","article-title":"STAT3: versatile functions in non-small cell lung cancer","volume":"12","author":"Mohrherr","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib206","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.3390\/cancers15235647","article-title":"Oligonucleotide-based therapeutics for STAT3 targeting in cancer\u2014drug carriers matter","volume":"15","author":"Molenda","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib207","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12645-024-00285-z","article-title":"Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC)","volume":"15","author":"Montazersaheb","year":"2024","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.ejphar.2025.178079_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26959","article-title":"Investigation the apoptotic effect of silver nanoparticles (Ag-NPs) on MDA-MB 231 breast cancer epithelial cells via signaling pathways","volume":"10","author":"Montazersaheb","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2025.178079_bib209","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137001","article-title":"Myeloid cell\u2013targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell\u2013mediated immunity","volume":"131","author":"Moreira","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.178079_bib210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.yexcr.2018.01.018","article-title":"STAT3 as a promising chemoresistance biomarker associated with the CD44+\/high\/CD24-\/low\/ALDH+ BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line","volume":"363","author":"Moreira","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib211","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007835","article-title":"Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NF\u03baB-IL-6 signalling axis","volume":"15","author":"Morgan","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejphar.2025.178079_bib212","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","article-title":"PARP inhibitors for breast cancer treatment: a review","volume":"10","author":"Morganti","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib213","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092292","article-title":"Paracrine IL-6 signaling confers proliferation between heterogeneous inflammatory breast cancer sub-clones","volume":"14","author":"Morrow","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib214","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/carcin\/bgac056","article-title":"HMGN4 plays a key role in STAT3-mediated oncogenesis of triple-negative breast cancer","volume":"43","author":"Mou","year":"2022","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejphar.2025.178079_bib215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040898","article-title":"CD44 targeted nanomaterials for treatment of triple-negative breast cancer","volume":"13","author":"Nabil","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib216","first-page":"157","article-title":"Nuclear expression of p-STAT3 is associated with poor prognosis in ER(\u2212)","volume":"12","author":"Nakagawa","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib217","first-page":"1609","article-title":"A perspective on anti-EGFR therapies targeting triple-negative breast cancer","volume":"6","author":"Nakai","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib218","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16208","article-title":"Binding of galectin-1 to integrin \u03b21 potentiates drug resistance by promoting survivin expression in breast cancer cells","volume":"8","author":"Nam","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178079_bib219","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3389\/fonc.2020.01206","article-title":"Biological landscape of triple negative breast cancers expressing CTLA-4","volume":"10","author":"Navarrete-Bernal","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041396","article-title":"Divide and conquer-targeted therapy for triple-negative breast cancer","volume":"26","author":"Nedeljkovi\u0107","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib221","article-title":"In situ tumor vaccination with nanoparticle Co-delivering CpG and STAT3 siRNA to effectively induce whole-body antitumor immune response","volume":"33","author":"Ngamcherdtrakul","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejphar.2025.178079_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119236","article-title":"Codelivery of STAT3 siRNA and BV6 by carboxymethyl dextran trimethyl chitosan nanoparticles suppresses cancer cell progression","volume":"581","author":"Nikkhoo","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178079_bib223","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055718","volume":"12","author":"Nishina","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejphar.2025.178079_bib224","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1387-5","article-title":"Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer","volume":"38","author":"Noblejas-L\u00f3pez","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib225","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cas.12683","article-title":"Phase I study of OPB\u201051602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed\/refractory hematological malignancies","volume":"106","author":"Ogura","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib226","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4143\/crt.2014.249","article-title":"Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors","volume":"47","author":"Oh","year":"2015","journal-title":"Cancer. Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib227","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/ijc.31585","article-title":"Flubendazole elicits anti\u2010metastatic effects in triple\u2010negative breast cancer via STAT3 inhibition","volume":"143","author":"Oh","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib228","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol. Int. : Official J. Japanese Soc. Allergol."},{"key":"10.1016\/j.ejphar.2025.178079_bib229","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10549-020-05613-6","article-title":"LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer","volume":"181","author":"Pan","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib230","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3390\/biomedicines10082003","article-title":"LLL12B, a novel small-molecule STAT3 inhibitor, induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer cells","volume":"10","author":"Pan","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178079_bib231","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/modpathol.2013.251","article-title":"High EGFR gene copy number predicts poor outcome in triple-negative breast cancer","volume":"27","author":"Park","year":"2014","journal-title":"Mod. Pathol. : Off. J. United States Canadian Acad. Pathol. Inc"},{"key":"10.1016\/j.ejphar.2025.178079_bib232","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/jmr.1047","article-title":"Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation","volume":"24","author":"Park","year":"2011","journal-title":"J. Mol. Recogn."},{"key":"10.1016\/j.ejphar.2025.178079_bib233","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.3390\/molecules28196783","article-title":"Bufotalin suppresses proliferation and metastasis of triple-negative breast cancer cells by promoting apoptosis and inhibiting the STAT3\/EMT Axis","volume":"28","author":"Park","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178079_bib234","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114053","article-title":"A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction","volume":"178","author":"Park","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11033-022-07921-0","article-title":"Ketoprofen suppresses triple negative breast cancer cell growth by inducing apoptosis and inhibiting autophagy","volume":"50","author":"Patra","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib236","article-title":"The role of NF-\u03baB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy","volume":"163","author":"Pavitra","year":"2023","journal-title":"Biomed. Pharmacotherapy Biomed. Pharmacotherapie"},{"key":"10.1016\/j.ejphar.2025.178079_bib237","doi-asserted-by":"crossref","first-page":"30943","DOI":"10.1021\/acsnano.3c12967","article-title":"Tumor-derived extracellular vesicles enable tumor tropism chemo-genetherapy for local immune activation in triple-negative breast cancer","volume":"18","author":"Peng","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejphar.2025.178079_bib238","doi-asserted-by":"crossref","DOI":"10.3390\/md22080370","article-title":"A new Renieramycin T right-half analog as a small molecule degrader of STAT3","volume":"22","author":"Phookphan","year":"2024","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejphar.2025.178079_bib239","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/03639045.2018.1539496","article-title":"Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells","volume":"45","author":"Pindiprolu","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejphar.2025.178079_bib240","first-page":"694","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.ejphar.2025.178079_bib241","series-title":"Seminars in Oncology","first-page":"132","article-title":"Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","author":"Prasad","year":"2017"},{"key":"10.1016\/j.ejphar.2025.178079_bib242","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114321","article-title":"Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer","volume":"236","author":"Pu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib243","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.18632\/aging.204967","article-title":"Acetyl-cinobufagin suppresses triple-negative breast cancer progression by inhibiting the STAT3 pathway","volume":"15","author":"Qi","year":"2023","journal-title":"Aging"},{"key":"10.1016\/j.ejphar.2025.178079_bib244","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s11655-023-3555-x","article-title":"Sanhuang xiexin decoction ameliorates TNBC by modulating JAK2-STAT3 and lipid metabolism","volume":"30","author":"Qi","year":"2024","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib245","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2025.14982","article-title":"Effects of SB939 are mediated by STAT3 to inhibit breast cancer cell metastasis-related genes","volume":"29","author":"Qin","year":"2025","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejphar.2025.178079_bib246","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","article-title":"STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review","volume":"38","author":"Qin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib247","first-page":"1415","article-title":"Natriuretic peptide receptor a promotes breast cancer development by upregulating MMP9","volume":"9","author":"Qu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib248","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.7150\/ijms.46925","article-title":"Arnicolide D inhibits triple negative breast cancer cell proliferation by suppression of Akt\/mTOR and STAT3 signaling pathways","volume":"17","author":"Qu","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib249","doi-asserted-by":"crossref","DOI":"10.3390\/ph17020225","article-title":"Unveiling epigenetic vulnerabilities in triple-negative breast cancer through 3D organoid drug screening","volume":"17","author":"Rao","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2025.178079_bib250","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/0008-5472.CAN-13-2433","article-title":"HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer","volume":"74","author":"Rath","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib251","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/cancers11091280","article-title":"STAT3, a master regulator of anti-tumor immune response","volume":"11","author":"R\u00e9b\u00e9","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib252","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib253","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.cmi.2020.05.030","article-title":"Tuberculosis sepsis after tocilizumab treatment","volume":"26","author":"Reisinger","year":"2020","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.ejphar.2025.178079_bib254","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/ptr.8143","article-title":"Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti-triple-negative breast cancer efficacy in vitro and in vivo","volume":"38","author":"Ren","year":"2024","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1056-8","article-title":"Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells","volume":"38","author":"Rigiracciolo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib256","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178079_bib257","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2018\/e478s","article-title":"DNA repair pathways and cisplatin resistance: an intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics"},{"key":"10.1016\/j.ejphar.2025.178079_bib258","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-57476-4","article-title":"Inhibition of the STAT3\/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer","volume":"16","author":"Rouault","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178079_bib259","first-page":"58","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.ejphar.2025.178079_bib260","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1007\/s11033-021-06701-6","article-title":"Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications","volume":"48","author":"Rubio-Tom\u00e1s","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib261","article-title":"STAT3 signaling in prostate cancer progression and therapy resistance: an oncogenic pathway with diverse functions","volume":"158","author":"Sadrkhanloo","year":"2023","journal-title":"Biomed. Pharmacotherapy Biomed. Pharmacotherapie"},{"key":"10.1016\/j.ejphar.2025.178079_bib262","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/13543784.2021.1891222","article-title":"An update on investigational therapies that target STAT3 for the treatment of cancer","volume":"30","author":"Santoni","year":"2021","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2025.178079_bib263","article-title":"Quantitative modelling explains distinct STAT1 and STAT3 activation dynamics in response to both IFN\u03b3 and IL-10 stimuli and predicts emergence of reciprocal signalling at the level of single cells","author":"Sarma","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejphar.2025.178079_bib264","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14728222.2018.1471137","article-title":"Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells","volume":"22","author":"Sasidharan Nair","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejphar.2025.178079_bib265","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10585-012-9475-3","article-title":"Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer","volume":"29","author":"Schoppmann","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ejphar.2025.178079_bib266","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/ijms19061591","article-title":"Structural biology of STAT3 and its implications for anticancer therapies development","volume":"19","author":"Sgrignani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib267","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/21691401.2022.2030746","article-title":"Co-delivery of STAT3 siRNA and methotrexate in breast cancer cells","volume":"50","author":"Shakeran","year":"2022","journal-title":"Artif. Cells, Nanomed. Biotechnol."},{"key":"10.1016\/j.ejphar.2025.178079_bib268","doi-asserted-by":"crossref","first-page":"692","DOI":"10.4062\/biomolther.2023.173","article-title":"Domperidone exerts antitumor activity in triple-negative breast cancer cells by modulating reactive oxygen species and JAK\/STAT3 signaling","volume":"31","author":"Shakya","year":"2023","journal-title":"Biomolec. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178079_bib269","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4062\/biomolther.2022.121","article-title":"Hydroxyzine induces cell death in triple-negative breast cancer cells via mitochondrial superoxide and modulation of jak2\/STAT3 signaling","volume":"30","author":"Shakya","year":"2022","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.ejphar.2025.178079_bib270","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/j.annonc.2020.08.451","volume":"31","author":"Sharma","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib271","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1186\/s12885-022-10225-y","article-title":"Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety","volume":"22","author":"Sharmni Vishnu","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib272","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108037","article-title":"Epidermal growth factor receptor mutations in breast Cancer: therapeutic challenges and way forward","volume":"154","author":"Shetty","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib273","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.3390\/curroncol31100426","article-title":"Bazedoxifene as a potential cancer therapeutic agent targeting IL-6\/gp130 signaling","volume":"31","author":"Shi","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib274","first-page":"3667","article-title":"MicroRNA-124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3","volume":"19","author":"Shi","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2025.178079_bib275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117507","article-title":"Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3","volume":"95","author":"Shih","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib276","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1101\/gad.316646.118","article-title":"Signaling pathways and steroid receptors modulating estrogen receptor \u03b1 function in breast cancer","volume":"32","author":"Siersb\u00e6k","year":"2018","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejphar.2025.178079_bib277","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","article-title":"IL6\/STAT3 signaling hijacks estrogen receptor \u03b1 enhancers to drive breast cancer metastasis","volume":"38","author":"Siersb\u00e6k","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2025.178079_bib278","article-title":"Suppression of breast cancer cell proliferation by selective single-domain antibody for intracellular STAT3. Breast Cancer Basic Clin","volume":"12","author":"Singh","year":"2018","journal-title":"Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib279","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1038\/s41388-018-0132-4","article-title":"Interaction between STAT3 and GLI1\/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer","volume":"37","author":"Sirkisoon","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2025.178079_bib280","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12307-018-0218-0","article-title":"Hypoxia induces the acquisition of cancer stem-like phenotype via upregulation and activation of signal transducer and activator of transcription-3 (STAT3) in MDA-MB-231, a triple negative breast cancer cell line","volume":"11","author":"Soleymani Abyaneh","year":"2018","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.ejphar.2025.178079_bib281","first-page":"1","article-title":"VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer","volume":"51","author":"Song","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib282","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2147\/CMAR.S225376","article-title":"EGFR promotes the development of triple negative breast cancer through JAK\/STAT3 signaling","author":"Song","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib283","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-022-06679-0","article-title":"STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression","volume":"196","author":"Song","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib284","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12916-015-0416-2","article-title":"Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer","volume":"13","author":"Sonnenblick","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.ejphar.2025.178079_bib285","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.7150\/ijbs.78554","article-title":"Chemical-proteomics identify peroxiredoxin-1 as an actionable target in triple-negative breast cancer","volume":"19","author":"Sp\u00ednola-Lasso","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib286","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/mc.22438","article-title":"Non-canonical Stat3 signaling in cancer","volume":"55","author":"Srivastava","year":"2016","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejphar.2025.178079_bib287","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-018-0060-z","article-title":"Phase II study of ruxolitinib, a selective JAK1\/2 inhibitor, in patients with metastatic triple-negative breast cancer","volume":"4","author":"Stover","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib288","first-page":"2317","article-title":"Active Stat3 and Her-2 as combined survival predictors show superiority to TNM staging system for postoperative patients with gastric cancer","volume":"14","author":"Sun","year":"2022","journal-title":"Am. J. Tourism Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib289","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00044-021-02775-w","article-title":"Osthole: an overview of its sources, biological activities, and modification development","volume":"30","author":"Sun","year":"2021","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.imbio.2005.11.004","article-title":"An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer","volume":"211","author":"Sun","year":"2006","journal-title":"Immunobiology"},{"key":"10.1016\/j.ejphar.2025.178079_bib291","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.clbc.2018.12.008","article-title":"Combined targeted therapies for first-line treatment of metastatic triple negative breast cancer-A phase II trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and Erlotinib","volume":"19","author":"Symonds","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib292","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3389\/fphar.2018.00642","article-title":"Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases","volume":"9","author":"Tai","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib293","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.865024","article-title":"Clinical relevance of estrogen reactivity in the breast cancer microenvironment","volume":"12","author":"Takeshita","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib294","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.3390\/cancers14215374","article-title":"The proliferative role of immune checkpoints in tumors: double regulation","volume":"14","author":"Tang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib295","doi-asserted-by":"crossref","first-page":"15977","DOI":"10.1074\/jbc.RA118.003719","article-title":"Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2","volume":"293","author":"Tegowski","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib296","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-024-07403-w","article-title":"BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436","volume":"208","author":"Teufelsbauer","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib297","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600573","article-title":"Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects","volume":"10","author":"Thomas","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib298","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2025.01.003","article-title":"Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: implications for cancer therapy","author":"Thuya","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejphar.2025.178079_bib299","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-019-05183-2","article-title":"Bazedoxifene is a novel IL-6\/GP130 inhibitor for treating triple-negative breast cancer","volume":"175","author":"Tian","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib300","doi-asserted-by":"crossref","first-page":"465","DOI":"10.31557\/APJCP.2025.26.2.465","article-title":"Plumbagin inhibits cadmium-induced interleukin-6\/STAT3 signaling in the triple-negative breast cancer cell line","volume":"26","author":"Titiwattanakarn","year":"2025","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ejphar.2025.178079_bib301","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/ERC-12-0194","article-title":"p42\/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth","volume":"20","author":"Tkach","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib302","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020429","article-title":"STAT3 signaling in breast cancer: multicellular actions and therapeutic potential","volume":"14","author":"To","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib303","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/ijms22020603","article-title":"The multifaced role of STAT3 in cancer and its implication for anticancer therapy","volume":"22","author":"Tolomeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib304","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1158\/1538-7445.AM2024-1196","article-title":"Peripheral immune analyses correlate with clinical outcome: a phase II trial of nivolumab, capecitabine, or the combination in patients with triple negative breast cancer","volume":"84","author":"Toney","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib305","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1535-7163.MCT-20-0505","article-title":"Lipidome-based targeting of STAT3-driven breast cancer cells using poly-l-glutamic acid\u2013coated layer-by-layer nanoparticles","volume":"20","author":"Tosic","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178079_bib306","doi-asserted-by":"crossref","first-page":"RP92873","DOI":"10.7554\/eLife.92873","article-title":"Structural dynamics of the active HER4 and HER2\/HER4 complexes is finely tuned by different growth factors and glycosylation","volume":"12","author":"Trenker","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.ejphar.2025.178079_bib307","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib308","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071511","article-title":"Targeting the IL-6\/STAT3 signalling cascade to reverse tamoxifen resistance in estrogen receptor positive breast cancer","volume":"13","author":"Tsoi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib309","series-title":"Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy","first-page":"7","article-title":"Molecular and cellular functions of CTLA-4","author":"Van Coillie","year":"2020"},{"key":"10.1016\/j.ejphar.2025.178079_bib310","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib311","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/cancers14051330","article-title":"Ipilimumab, pembrolizumab, or nivolumab in combination with BBI608 in patients with advanced cancers treated at MD anderson cancer center","volume":"14","author":"Vo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib312","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2024.100119","article-title":"Microarray analysis of differentially expressed miRNA in triple negative breast cancer: a study of western India","volume":"10","author":"Vora","year":"2024","journal-title":"Adv. Cancer Biol. Metasta"},{"key":"10.1016\/j.ejphar.2025.178079_bib313","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.breast.2022.06.007","article-title":"Anthracyclines in the treatment of early breast cancer friend or foe?","volume":"65","author":"Vuger","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ejphar.2025.178079_bib314","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10911-008-9062-z","article-title":"Jak2\/Stat5 signaling in mammogenesis, breast cancer initiation and progression","volume":"13","author":"Wagner","year":"2008","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.ejphar.2025.178079_bib315","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102268","article-title":"Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice","volume":"35","author":"Wang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178079_bib316","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.124","article-title":"STAT3 pathway in cancers: past, present, and future","volume":"3","author":"Wang","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejphar.2025.178079_bib317","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22039","article-title":"Interleukin\u20106 contributes to chemoresistance in MDA\u2010MB\u2010231 cells via targeting HIF\u20101\u03b1","volume":"32","author":"Wang","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178079_bib318","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3390\/cancers16091705","article-title":"Survivin as a therapeutic target for the treatment of human cancer","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib319","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bbrc.2018.07.088","article-title":"Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3\/MAPKs\/AKT signaling pathways","volume":"503","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2025.178079_bib320","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","article-title":"The role of STAT3 in leading the crosstalk between human cancers and the immune system","volume":"415","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178079_bib321","article-title":"p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2025.178079_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2024.07.003","article-title":"Targeting the STAT3 pathway with STAT3 degraders","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib323","first-page":"276","article-title":"Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level","volume":"13","author":"Wegenka","year":"1993","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178079_bib324","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.1164551","article-title":"Function of mitochondrial Stat3 in cellular respiration","volume":"323","author":"Wegrzyn","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.178079_bib325","first-page":"9008","volume":"21","author":"Weinberg","year":"2020"},{"key":"10.1016\/j.ejphar.2025.178079_bib326","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1124\/jpet.119.256818","article-title":"Cancer and the dopamine D2 receptor: a pharmacological perspective","volume":"370","author":"Weissenrieder","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178079_bib327","first-page":"1","article-title":"Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer","author":"Witt","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2025.178079_bib328","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115475","article-title":"Activated stat3 is a novel regulator of the xrcc1 promoter and selectively increases xrcc1 protein levels in triple negative breast cancer","volume":"22","author":"Wright","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178079_bib329","doi-asserted-by":"crossref","DOI":"10.3390\/cells12081156","article-title":"Autophagy and breast cancer: connected in growth, progression, and therapy","volume":"12","author":"Wu","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178079_bib330","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216508","article-title":"A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer","volume":"581","author":"Wu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178079_bib331","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154769","article-title":"\u03b2, \u03b2-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis","volume":"114","author":"Wu","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejphar.2025.178079_bib332","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.yexcr.2017.05.007","article-title":"MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3","volume":"357","author":"Xiang","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib333","article-title":"L3MBTL3 and STAT3 collaboratively upregulate SNAIL expression to promote metastasis in female breast cancer","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178079_bib334","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0744-3","article-title":"Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6\/STAT3 pathway","volume":"12","author":"Xie","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib335","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092424","article-title":"An Isoxazoloquinone derivative inhibits tumor growth by targeting STAT3 and triggering its ubiquitin-dependent degradation","volume":"15","author":"Xie","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178079_bib336","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.164697","article-title":"Ferritin nanocages facilitate PROTAC delivery for enhanced targeted therapy in triple-negative breast cancer","volume":"518","author":"Xu","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejphar.2025.178079_bib337","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70071","article-title":"A novel synthesised STAT3 inhibitor exerts potent anti-tumour activity by inducing lysosome-dependent cell death","author":"Xu","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib338","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41523-022-00472-4","article-title":"High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes","volume":"8","author":"Xu","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib339","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14786419.2017.1396596","article-title":"Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer","volume":"33","author":"Yang","year":"2019","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib340","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.63","article-title":"Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178079_bib341","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-022-06790-2","article-title":"Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis","volume":"197","author":"Yang","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178079_bib342","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib343","doi-asserted-by":"crossref","DOI":"10.3390\/ncrna8010008","article-title":"Direct comparison of chol-siRNA polyplexes and chol-DsiRNA polyplexes targeting STAT3 in a syngeneic murine model of TNBC","volume":"8","author":"Ye","year":"2022","journal-title":"Non-coding RNA"},{"key":"10.1016\/j.ejphar.2025.178079_bib344","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648139","article-title":"Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives","volume":"11","author":"Yi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib345","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155729","article-title":"Direct and indirect modulation of STAT3\/CSE\/H(2)S axis in triple negative breast cancer by non-coding RNAs: MALAT-1 lncRNA, miR-486-5p and miR-30a-5p","volume":"265","author":"Youness","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejphar.2025.178079_bib346","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-21-0747","article-title":"PDSS1-Mediated activation of CAMK2A-STAT3 signaling promotes metastasis in triple-negative breast cancer","volume":"81","author":"Yu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib347","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29219\/fnr.v68.10974","article-title":"Inhibition of triple-negative breast cancer growth via delphinidin-mediated suppression of the JAK2\/STAT3\/PD-L1 pathway","volume":"68","author":"Yu","year":"2024","journal-title":"Food Nutr. Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib348","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-025-04770-z","article-title":"Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function","volume":"95","author":"Yuan","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib349","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtice.2023.104673","article-title":"Small-molecule inhibitor of Fam20C in combination with paclitaxel suppresses tumor growth by LIF-JAK2\/STAT3-modulated apoptosis in triple-negative breast cancer","volume":"143","author":"Yuan","year":"2023","journal-title":"J. Taiwan Inst. Chem. Eng."},{"key":"10.1016\/j.ejphar.2025.178079_bib350","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102357","article-title":"Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors","volume":"35","author":"Zhang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178079_bib351","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106541","article-title":"Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors","volume":"136","author":"Zhang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib352","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3892\/ijo.2024.5636","article-title":"Role of STAT3 in cancer cell epithelial-mesenchymal transition","volume":"64","author":"Zhang","year":"2024","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib353","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/stem.1795","article-title":"MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway","volume":"32","author":"Zhang","year":"2014","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejphar.2025.178079_bib354","article-title":"Current landscape of personalized clinical treatments for triple-negative breast cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib355","article-title":"Self-assembled dual-targeting nanoplatform for synergistic photodynamic and PROTAC-mediated metabolic starvation in triple-negative breast cancer","volume":"520","author":"Zhang","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejphar.2025.178079_bib356","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2015-08-665604","article-title":"Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178079_bib357","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.153939","article-title":"Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR\/JAK1\/STAT3 pathway to inhibit PD-1\/PD-L1 checkpoint signaling","volume":"99","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejphar.2025.178079_bib358","doi-asserted-by":"crossref","first-page":"14150","DOI":"10.1021\/acs.jmedchem.3c01242","article-title":"Discovery of novel fedratinib-based HDAC\/JAK\/BRD4 triple inhibitors with remarkable antitumor activity against triple negative breast cancer","volume":"66","author":"Zhao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib359","article-title":"Niraparib-induced STAT3 inhibition increases its antitumor effects","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178079_bib360","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000490025","article-title":"Evolving roles for targeting CTLA-4 in cancer immunotherapy","volume":"47","author":"Zhao","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2025.178079_bib361","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41401-021-00718-0","article-title":"The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts","volume":"43","author":"Zhong","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2025.178079_bib362","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/science.8140422","article-title":"Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6","volume":"264","author":"Zhong","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.178079_bib363","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1021\/acsmedchemlett.1c00155","article-title":"SD-91 as A Potent and selective STAT3 degrader capable of achieving complete and long-lasting tumor regression","volume":"12","author":"Zhou","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2025.178079_bib364","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib365","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12935-024-03270-z","article-title":"SLC25A17 inhibits autophagy to promote triple-negative breast cancer tumorigenesis by ROS-mediated JAK2\/STAT3 signaling pathway","volume":"24","author":"Zhou","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2025.178079_bib366","doi-asserted-by":"crossref","first-page":"943","DOI":"10.32604\/or.2023.044775","article-title":"Metochalcone induces senescence-associated secretory phenotype via JAK2\/STAT3 pathway in breast cancer","volume":"32","author":"Zhou","year":"2024","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejphar.2025.178079_bib367","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41416-022-01794-7","article-title":"SBSN drives bladder cancer metastasis via EGFR\/SRC\/STAT3 signalling","volume":"127","author":"Zhou","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178079_bib368","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.153065","article-title":"Arnicolide D exerts anti-melanoma effects and inhibits the NF-\u03baB pathway","volume":"64","author":"Zhu","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejphar.2025.178079_bib369","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1515\/hsz-2016-0104","article-title":"MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancer","volume":"397","author":"Zhu","year":"2016","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178079_bib370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116268","article-title":"Serine\/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer","volume":"225","author":"Zhu","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178079_bib371","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neo.2020.10.012","article-title":"Eucannabinolide, a novel sesquiterpene lactone, suppresses the growth, metastasis and BCSCS-like traits of TNBC via inactivation of STAT3","volume":"23","author":"Zhu","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejphar.2025.178079_bib372","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:39:06Z","timestamp":1762144746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":372,"alternative-id":["S0014299925008337"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178079","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting STAT3 pathway: A promising immunotherapeutic strategy for triple-negative breast cancer \u2013 Current status and future outlooks","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178079"}}